David Kagan Selected Research

Ganglioneuroma

12/2004

Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Kagan Research Topics

Disease

2	Disease Progression 01/2015 - 05/2008
1	Pain (Aches) 01/2022
1	Heart Failure 01/2017
1	Renal Insufficiency (Renal Failure) 01/2015
1	Fibrosis (Cirrhosis) 01/2015
1	Kidney Diseases (Kidney Disease) 01/2015
1	Hereditary Nephritis (Alport Syndrome) 01/2015
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2015
1	Endometriosis 08/2010
1	Experimental Arthritis 08/2010
1	Inflammation (Inflammations) 05/2008
1	Ganglioneuroma 12/2004
1	Neoplasms (Cancer) 12/2004

Drug/Important Bio-Agent (IBA)

2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2010 - 05/2008
1	SteroidsIBA 01/2022
1	Neprilysin (Neutral Endopeptidase)IBA 01/2017
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2017
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2017
1	CollagenIBA 01/2015
1	Clodronic Acid (Clodronate)IBA 01/2015
1	Liposomes (Liposome)IBA 01/2015
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 08/2010
1	Carrier Proteins (Binding Protein)IBA 08/2010
1	Proteins (Proteins, Gene)FDA Link 08/2010
1	CytokinesIBA 08/2010
1	Biomarkers (Surrogate Marker)IBA 05/2008
1	Thrombospondin 1IBA 12/2004

Therapy/Procedure

1	Injections 01/2022
1	Therapeutics 01/2015